References
- Zhou J, Enewold L, Stojadinovic A et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control21, 853–861 (2010).
- Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol.26, 3063–3072 (2008).
- Fischer L, Kleeff J, Esposito I et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br. J. Surg.95, 627–635 (2008).
- Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology135, 1469–1492 (2008).
- Fischer L, Mehrabi A, Büchler MW. [Neuroendocrine tumors of the duodenum and pancreas: surgical strategy]. Chirurg82(7), 583–590 (2011).
- Kloppel G, Rindi G, Perren A et al. The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment. Pathologe31, 353–354 (2010).
- Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer12, 1083–1092 (2005).
- Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer113, 2655–2664 (2008).
- Cheng PNM, Saltz LB. Failure to confirm major objective anti-tumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer86, 944–948 (1999).
- Bajetta E, Procopio G, Ferrari L et al. Update on the treatment of neuroendocrine tumors. Expert Rev. Anticancer Ther.3, 631–642 (2003).
- Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol.22, 4762–4771 (2004).
- McCollum AD, Kulke MH, Ryan DP et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am. J. Clin. Oncol.27, 485–488 (2004).
- Rinke A, Móller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol.27, 4656–4663 (2009).
- Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med.364, 514–523 (2011).
- Raymond E, Dahan L, Raoul J-L et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med.364, 501–513 (2011).
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
- Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol.28, 69–76 (2010).
- O’Donnell A, Faivre S, Burris HA III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol.26, 1588–1595 (2008).
- Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT–mTOR pathway. J. Clin. Oncol.28, 245–255 (2010).
- Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell1, 193–202 (2002).
- Fjallskog ML, Hessman O, Eriksson B, Janson ET. Upregulated expression of PDGF receptor β in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol.46, 741–746 (2007).
- Hansel DE, Rahman A, Hermans J et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod. Pathol.16, 652–659 (2003).
- Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov.6, 734–745 (2007).
- Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol.23, 939–952 (2005).
- Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol.26, 3403–3410 (2008).